Preparation method of anti-inflammatory, anti-oxidation and anti-protein adsorption bi-crosslinking hydrogel and application of anti-inflammatory, anti-oxidation and anti-protein adsorption bi-crosslinking hydrogel in prevention and treatment of tissue adhesion

Through the design of the double crosslinked hydrogel, the prevention problem of postoperative tissue adhesion is solved, and the intelligent drug release and anti-adhesion effect in the postoperative trauma site is achieved, with strong mechanical properties and good clinical application prospects.

CN118903565APending Publication Date: 2024-11-08SUN YAT SEN UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410765447.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has problems such as single barrier function, insufficient mechanical strength, uncontrollable drug release and difficulty in covering complex wounds in preventing postoperative tissue adhesions, and existing gel-like materials have not effectively inhibited the formation of adhesions.

Method used

Anti-inflammatory, antioxidant and anti-protein adsorption double crosslinked hydrogel consisting of polyvinyl alcohol derivative PSC and hyaluronic acid derivative AHBC, which has strong mechanical properties through dynamic imine bonds and borate ester bonds. , and intelligently release anti-inflammatory and antioxidant drugs in the trauma site to resist fibrin adsorption.

Benefits of technology

It realizes the release of intelligent drugs in postoperative trauma sites, effectively reduces inflammation and oxidative stress, enhances anti-adhesion effect, has good clinical application prospects and mechanical strength, and is suitable for complex wound coverage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_4
    Figure FT_4
Patent Text Reader

Abstract

The invention discloses a postoperative tissue adhesion prevention double-crosslinking hydrogel with anti-inflammatory, anti-oxidation and anti-protein adsorption functions and a preparation method thereof. The hydrogel disclosed by the invention is prepared by forming dynamic covalent imine bonds and boric acid ester bonds between a polyvinyl alcohol derivative modified by p-hydroxybenzaldehyde and sulfated betaine and a hyaluronic acid derivative modified by phenylboronic acid and adipic dihydrazide groups; wherein the phenylboronic acid of the hyaluronic acid derivative is also covalently grafted with an anti-inflammatory and antioxidant drug containing a polyphenol group through an active oxygen responsive borate bond. The hydrogel disclosed by the invention can be rapidly gelatinized on the surface of a wound in situ so as to cover an irregular wound surface, and has stronger mechanical properties than that of single-bond cross-linked hydrogel; the anti-inflammatory and anti-oxidation drug covalently loaded in the hydrogel can respond to wound active oxygen release, various active oxygen is removed, and then oxidative stress and inflammatory response are relieved. In addition, sulfated betaine zwitterions modified on a hydrogel skeleton can resist adsorption of fibrin and fibroblasts, so that an excellent postoperative adhesion resisting effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0003] The invention belongs to the technical field of biomedical materials, and specifically relates to a preparation method of an anti-inflammatory, anti-oxidative and anti-protein adsorption double-crosslinked hydrogel and an application of the hydrogel in preventing and treating postoperative tissue adhesion. Background Art

[0005] Postoperative tissue adhesion refers to tissue damage after surgery, which then forms fibrous adhesions between the damaged area and adjacent tissues and organs. It is the most common complication after clinical surgical operations, especially abdominal surgery. It is reported that up to 90% of patients undergoing abdominal / pelvic surgery will develop secondary tissue adhesions, which will then cause a series of serious complications such as severe abdominal pain, intestinal obstruction, and secondary infertility, which will seriously reduce the quality of life of patients and even endanger their lives. Secondary surgery is currently the only effective treatment for clinically relieving adhesions, but it can only temporarily relieve obstruction and has a high postoperative recurrence rate. Recurrent adhesions are usually more complicated and difficult to prevent than initial adhesions. Therefore, the prevention of adhesions is extremely important.

[0006] At present, the clinical strategies for preventing adhesion mainly include improving surgical skills, drug treatment, and the use of anti-adhesion barrier materials. Compared with open surgery, laparoscopic surgery can effectively reduce intraoperative damage, and thus is expected to reduce the risk of adhesion formation. However, laparoscopic surgery can only reduce the scope and severity of adhesions, and cannot significantly inhibit the formation of adhesions. Systemic or local direct administration of anticoagulants, anti-inflammatory drugs, antioxidants, cytokines, antibodies, fibrinolytic agents, etc. have limitations such as rapid drug clearance, uncontrollable dosage, and increased risk of bleeding. Currently, there is no drug that can effectively inhibit the formation of adhesions when used alone. Based on the limitations of the above two strategies, anti-adhesion biological barrier materials are currently the most widely used in clinical practice. They exert anti-adhesion effects by physically separating the damaged peritoneum from the surrounding adjacent tissues / organs, mainly including solution-type, film-type, and gel-type barriers. However, different types of physical barrier products currently available on the market have their own defects. Solution-type barriers such as Adept ® , strong fluidity, rapid absorption in the body, and short local retention time. ® Strict hemostasis is required during application, Seprafilm ® When applied, they strongly adhere to any wet surface, affecting surgical operations, and both are difficult to cover irregular wounds and are difficult to be compatible with minimally invasive laparoscopic surgery. Widely used gel barriers, such as medical sodium hyaluronate gel, have problems such as poor mechanical strength and rapid degradation in the body. In addition, the existing anti-adhesion products on the market only play a single barrier function and do not prevent and treat adhesions from the perspective of the pathological cascade of adhesion occurrence and development. Therefore, it is urgent to develop new biomedical materials that combine excellent barrier properties and therapeutic functions to effectively prevent the occurrence of adhesions.

[0007] Studies have shown that the formation of postoperative tissue adhesion is a complex physiological process, in which excessive inflammatory response and oxidative stress after trauma are key factors in adhesion formation. In addition, abnormal deposition of fibrin at the wound site and adsorption of fibroblasts also play an important role in adhesion formation. Therefore, while enhancing the mechanical strength of the barrier, it is important to effectively reduce the oxidative stress and inflammation level of the wound surface and prevent fibrin deposition for adhesion prevention. Summary of the invention

[0009] Based on the above situation, the present invention provides a method for preparing a double cross-linked hydrogel with anti-inflammatory, anti-oxidation and anti-protein adsorption and anti-adhesion properties. The hydrogel is prepared by cross-linking a dynamic imine bond and a borate bond, and can quickly form gel in situ on the wound surface to cover irregular wounds, and has stronger mechanical properties than single-bond cross-linked hydrogels; the covalently loaded anti-inflammatory and antioxidant drugs in the hydrogel can respond to the release of reactive oxygen species on the wound surface, relieve oxidative stress and inflammatory response, and the zwitterions modified on the hydrogel skeleton can resist the adsorption of fibrin and fibroblasts, thereby exerting an excellent anti-postoperative adhesion effect; it has good clinical transformation prospects and application value.

[0010] To achieve the above purpose, the technical solution adopted by the present invention is:

[0011] A double cross-linked hydrogel with anti-inflammatory, antioxidant and anti-protein adsorption properties, characterized in that it is composed of two gel precursor materials, a polyvinyl alcohol derivative PSC and a hyaluronic acid derivative AHBC. The structural feature of the PSC is that p-hydroxybenzaldehyde and sulfated betaine are covalently modified on some hydroxyl groups of the polyvinyl alcohol. The structural feature of the AHBC is that hyaluronic acid is co-modified with 3-fluorophenylboronic acid and adipic dihydrazide groups, and anti-inflammatory and antioxidant drugs containing polyphenol groups are further grafted on the phenylboronic acid through active oxygen responsive boric acid ester bonds. After the AHBC solution is mixed with the PSC solution, the hydrazide group and the boric acid group in the AHBC react with the aldehyde group and the 1,3-diol group on the PSC respectively to generate dynamic covalent acylhydrazone bonds and boric acid ester bonds, thereby obtaining a double cross-linked active oxygen responsive anti-inflammatory and antioxidant hydrogel.

[0012]

[0013] In the PSC structure, n is a natural number between 250 and 2000;

[0014]

[0015] In the AHBC structure, n is a natural number ranging from 25 to 1000, and A4 is an anti-inflammatory and antioxidant drug containing a polyphenol group.

[0016] The anti-inflammatory and antioxidant drug containing polyphenol groups is one of chlorogenic acid, epigallocatechin gallate, and tannic acid; the degree of substitution of the B1 group in the PSC structure is 0.1%-0.5%, and the degree of substitution of the B2 group is 1%-5%; the degree of substitution of the A1 group in the AHBC structure is 30%-40%, and the degree of substitution of the A2 group is 30%-40%.

[0017] The present invention also provides a method for preparing an anti-inflammatory, anti-oxidative and anti-protein adsorption double cross-linked hydrogel, comprising the steps of:

[0018] Step 1, synthesizing gel precursor material AHBC;

[0019] Step 2, synthesizing gel precursor material PSC;

[0020] Step 3, dissolving AHBC and PSC in aqueous media to prepare solutions, and then mixing the AHBC solution and the PSC solution to prepare an anti-inflammatory, antioxidant and anti-protein adsorption double cross-linked hydrogel.

[0021] The synthesis of AHBC comprises the following steps:

[0022] First, PBA-NH2 is synthesized using PBA as raw material, and the reaction formula is as follows:

[0023]

[0024] Next, PBA-NH2 and hyaluronic acid HA are used as raw materials to synthesize HA-PBA through an amide condensation reaction, and then HA-PBA and ADH are used as raw materials to synthesize ADH-HA-PBA through an amide condensation reaction. Finally, ADH-HA-PBA is reacted with an anti-inflammatory and antioxidant drug C containing a polyphenol group to synthesize the precursor material AHBC; the reaction formula is as follows:

[0025]

[0026] The synthesis of the PSC comprises the following steps:

[0027] First, DPE-SB is synthesized using DPE as a synthetic raw material, and the reaction formula is as follows:

[0028]

[0029] Then, PVA is reacted with succinic anhydride to synthesize PVA-COOH, and then PVA-COOH is reacted with DPE-SB to synthesize PVA(SB), and finally PVA(SB) is reacted with p-hydroxybenzaldehyde to synthesize PSC; the reaction formula is as follows:

[0030]

[0031] In some of the embodiments, the concentration of AHBC is 2.5wt%~7.5wt%; the concentration of PSC is 2.5wt%~7.5wt%; the mixing method of the AHBC solution and the PSC solution is in-situ mixing of the application part; the mixing method is injection or spray mixing.

[0032] Another object of the present invention is to provide a use of the above-mentioned anti-inflammatory, antioxidant and anti-protein adsorption double-crosslinked hydrogel in the preparation of a biological barrier against postoperative tissue adhesion.

[0033] In some embodiments, the postoperative tissue adhesion includes any one or more of abdominal adhesion, uterine adhesion, and pericardial adhesion.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] (1) The hydrogel provided by the present invention can intelligently release natural polyphenol anti-inflammatory and antioxidant drugs on demand according to the level of reactive oxygen species at the postoperative trauma site, thereby removing reactive oxygen species and alleviating oxidative stress and inflammatory response. It overcomes the limitations of anti-inflammatory and antioxidant drugs that are present in the single administration of anti-inflammatory and antioxidant drugs, such as rapid drug clearance and uncontrollable dosage, as well as the problem of uncontrollable drug release from physically encapsulated drugs in the gel. It also overcomes the problem that existing gel materials in clinical practice only play a physical barrier role and do not prevent adhesion based on its discovery mechanism.

[0036] (2) The hydrogel provided by the present invention can effectively resist the adsorption of fibrin and fibroblasts, and combined with anti-inflammatory and antioxidant functions, it can enhance the prevention and treatment effect of postoperative tissue adhesion from different dimensions of regulating the occurrence and development of adhesion.

[0037] (3) The hydrogel provided by the present invention can be rapidly formed in situ at the site of trauma during surgery, can cover complex tissue wounds, has good mechanical strength and is compatible with laparoscopic surgery, and can effectively play a physical barrier function during the critical period of adhesion occurrence (within 7 days). BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The specific embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings, wherein:

[0040] Figure 1 This is the NMR image of AHBC represented by chlorogenic acid in Example 1.

[0041] Figure 2 This is the NMR image of the PSC in Example 2.

[0042] Figure 3 Macroscopic images of (A) injectability and (BC) spray film-forming properties of AHBC / PSC hydrogel in Example 3

[0043] Figure 4 The infrared spectrum of AHBC / PSC hydrogel in Example 3

[0044] Figure 5 Strain scanning curves of AHBC / PSC hydrogel and single network hydrogels HA-ADH / PC and AHBC / PSC in comparative example 1 (frequency 1 Hz, strain range 0.1%-100%); (B) elastic model and quantified value of viscous modulus (frequency 1 Hz, strain 1%, time scanning 3 min).

[0045] Figure 6 The ability of different hydrogels in comparative example 2 to remove (A) DPPH and (B) •OH

[0046] Figure 7 The relative expression levels of iNOS and Arg-1 mRNA after incubation of RAW 264.7 cells with different concentrations of chlorogenic acid (CGA) or AHBC / PSC hydrogel extract containing chlorogenic acid in Example 4

[0047] Figure 8 Comparison of the adsorption capacity of different hydrogels on BSA protein in Comparative Example 3

[0048] Fig. 9 Cumulative release curve of AHBC / PSC hydrogel in Example 4 in PBS (pH 7.4) buffer containing different concentrations of H2O2 (0 μM, 100 μM, 300 μM and 500 μM)

[0049] Fig.10 is the relative residual mass of the AHBC / PSC hydrogel and the commercially available HA hydrogel on the cecum surface at different time points in Example 5

[0050] Fig.11 The adhesion scores of each group at 7 and 14 days after surgery in Example 6 are shown in Table 6. DETAILED DESCRIPTION

[0052] The preferred embodiments of the invention are described below in conjunction with the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the invention, and are not used to limit the invention.

[0053] The method involved in the present invention is a known method in the art, and the reagents and cells related to the experiment can be obtained through commercial channels.

[0054] Example 1: Synthesis of hydrogel precursor material AHBC:

[0055] 1) Synthesis of HA-PBA: Weigh 5.00 g of HA and dissolve it in 300 mL of pure water, then add 2.06 g of DMTMM and stir at room temperature for 1 h. Weigh 2.53 g of PBA-NH2 and dissolve it in 20 mL of pure water and adjust the pH to neutral, then add it to the above activated HA solution and adjust the pH to 6.5 with 1M hydrochloric acid. After reacting for 24 h, dialyze the reaction solution against pure water for 2 d and freeze-dry to obtain white solid HA-PBA.

[0056] 2) Synthesis of ADH-HA-PBA: Weigh 4.00 g of HA-PBA and dissolve it in 240 mL of pure water. Adjust the pH of the solution to 4-5 with 0.1 M hydrochloric acid, then add 2.06 g of ADH and 0.250 g of EDCI. After stirring at room temperature for 2.5 h, add 0.1 M NaOH solution to adjust the pH to 7.0 to terminate the reaction. Filter the reaction solution, dialyze the filtrate with pure water for 2 days, and freeze-dry to obtain white solid ADH-HA-PBA.

[0057] 3) Synthesis of AHBC: Weigh 2.00 g of ADH-HA-PBA and dissolve it in 120 mL of pure water; weigh 0.328 g of chlorogenic acid, an anti-inflammatory and antioxidant drug, and dissolve it in 80 mL of DMSO, and add it to the above ADH-HA-PBA aqueous solution under N2 protection. After stirring at room temperature in the dark for 24 h, the reaction solution was dialyzed against pure water for 2 days and freeze-dried to obtain white solid AHBC.

[0058] The synthesis reaction formula of AHBC, taking the boronate bond grafted anti-inflammatory antioxidant drug chlorogenic acid as an example, is as follows:

[0059]

[0060] According to the same method, epigallocatechin gallate and tannic acid were used instead of chlorogenic acid to synthesize the gel precursor material grafted with the two drugs.

[0061] Example 2: Synthesis of hydrogel precursor material PSC:

[0062] 1) Synthesis of PVA-SB: Weigh 5.00 g of PVA and dissolve it in 100 mL of dimethyl sulfoxide, then add 0.5 g of succinic anhydride and 0.25 g of DMAP. After stirring at room temperature for 24 h, slowly add the reaction solution dropwise to a 10-fold amount of acetonitrile / ethanol (8:1, v / v) mixed solvent to precipitate, discard the supernatant, wash twice with the mixed solvent, then wash twice with ethanol, and dry at 50°C to obtain a white solid PVA-COOH. Then, weigh 5.00 g of PVA-COOH and dissolve it in 200 mL of pure water, add 2.40 g of DMTMM, and stir for 0.5 h; weigh 4 g of DPE-SB and dissolve it in 40 mL of pure water, adjust the pH to neutral with 1M NaOH solution, then add it to the PVA-COOH solution, adjust the pH to 6.5 with 1M HCl, and stir at room temperature for 24 h. After the reaction was completed, the reaction solution was dialyzed against pure water for 2 days and freeze-dried to obtain off-white solid PVA-SB.

[0063] 2) Synthesis of PSC: Weigh 4.00 g of PVA-SB and dissolve it in 150 mL of dimethyl sulfoxide. Add 2.00 g of p-formylbenzoic acid, 0.16 g of DMAP and 2.75 g of DCC, which were previously dissolved in dimethyl sulfoxide, dropwise into the above solution in sequence. After stirring at room temperature for 24 h, add dropwise into 10 times the amount of methanol (v / v) to precipitate. Wash the precipitate twice with methanol and then twice with ethanol. Then, heat and dissolve the product in 200 mL of pure water. Filter again to remove insoluble impurities, dialyze against pure water for 2 d, and freeze-dry to obtain an off-white solid PSC.

[0064] The synthetic reaction formula of PSC is as follows:

[0065]

[0066] Example 3: Synthesis and characterization of AHBC / PSC hydrogel:

[0067] AHBC 25 mg, AHBC 50 mg, and AHBC 75 mg were dissolved in 1 mL of deionized water to prepare 2.5 wt%, 5 wt%, and 7.5 wt% aqueous solutions, respectively. PSC 25 mg, PSC 50 mg, and PSC 75 mg were dissolved in 1 mL of deionized water to prepare 2.5 wt%, 5 wt%, and 7.5 wt% aqueous solutions, respectively. AHBC solutions with the same concentration were mixed with PSC solutions at a volume ratio (AHBC / PSC) of 5:1, 3:1, 1:3, and 1:5 to prepare hydrogels with different ratios. Physiological saline, pH 7.4 PBS buffer, and cell culture medium were used instead of deionized water to prepare hydrogels containing different aqueous media. The other three control hydrogels AHB / PC (without drug and without zwitterions), AHBC / PC (with drug but without zwitterions), and AHB / PSC (with zwitterions but without drug) were prepared in the same way.

[0068] 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution were loaded into a spray device, and the same spray speed was set. The precursor solution was sprayed onto the surface of the culture dish and the rat cecum. It can quickly form a uniform gel film on the surface of the culture dish or the cecum, and the macroscopic stretchability of the hydrogel was observed with the help of tools. 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution were loaded into a two-way syringe to investigate the injectability of the hydrogel. 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution were mixed in a volume ratio of 1:1 to prepare a hydrogel. After the hydrogel was freeze-dried, its microscopic morphology was observed using a scanning electron microscope (SEM). At the same time, the structure of the freeze-dried hydrogel was investigated using a Fourier transform infrared spectrometer.

[0069] The experimental results show that ( Figure 3-4 ): The hydrogel has good injectability. After spray mixing, it can form a uniform gel film. The film is dense and has good ductility. It can effectively isolate objects from the outside world and act as a physical barrier ( Figure 3 The gelation mechanism of AHBC / PSC was investigated by infrared spectroscopy ( Figure 4 ). The characteristic absorption peaks of HA and PVA appeared in AHBC, PSC and AHBC / PSC, including 3295 cm -1 The hydroxyl (OH) stretching vibration peak at 2919 cm -1 The carbon-hydrogen (CH) stretching vibration peak at 1038 cm -1 The carbon oxygen (CO) stretching vibration peak at 1316 cm -1The stretching vibration peak of borane (BO) appeared at 1311 cm-1. In AHBC / PSC, phenylboronic acid and 1,3-diol formed phenylboronic acid ester, and the stretching vibration peak of borane (BO) shifted to 1311 cm-1. -1 In AHBC / PSC, due to the Schiff base reaction between adipic dihydrazide and aldehyde groups, an acylhydrazone bond was formed. The stretching vibration peak of the imine (C=N) in the acylhydrazone bond was located at 1645 cm -1 The carbonyl (C=O) stretching vibration peak (1646 cm -1 However, it overlaps with the carbonyl group (C=O) in the aldehyde group, ester group and amide bond in PSC at 1714 cm -1 Compared with the stretching vibration at 1709 cm -1 A new carbonyl (C=O) stretching vibration peak appeared at , which may be related to the carbonyl group moving to a high wave number after the aldehyde group and hydrazide formed an acylhydrazone bond. In summary, the AHBC / PSC hydrogel produced borate ester bonds and acylhydrazone bonds through the reaction between monomer molecules, and finally formed a double cross-linked hydrogel.

[0070] Comparative Example 1: Comparison of mechanical strength between AHBC / PSC double cross-linked hydrogel and control single cross-linked hydrogel:

[0071] The rheological properties of the double cross-linked hydrogel formed by 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution in a volume ratio of 1:1 were investigated. Two single cross-linked hydrogels, HA-PBA / PVA and HA-ADH / PC, were prepared in the same way as controls. The basic parameters of the rheometer were set as follows: the measuring fixture was cone-plate CP20, the gap was 1 mm, the test temperature was 25°C, and the air pressure was 5 bar. The fixed frequency was 1 Hz, and the strain sweep test was performed in the range of 0.1%-100%;

[0072] The experimental results show that ( Figure 5 ): G' of each group of hydrogels is greater than G" in the strain range of 1%~30%, and the values ​​are basically stable, indicating that they exhibit stable hydrogel properties in the low strain area. The G' and G" of HA-PBA / PVA single-crosslinked hydrogel are close, and the Tan δ value is close to 1. The hydrogel shows strong toughness, but its strength is insufficient. The Tan δ value of HA-ADH / PC hydrogel is lower than 0.1, and the viscoelasticity is poor. The hydrogel shows hard and brittle characteristics. The Tan δ of the double-crosslinked hydrogel AHBC / PSC is about 0.5, and its viscoelastic value is close to that of soft tissues such as muscle and fat in the body (0.2-0.6).

[0073] Comparative Example 2: Comparison of the in vitro active oxygen scavenging ability of AHBC / PSC hydrogel and control hydrogel:

[0074] AHBC / PSC hydrogels with different weights (4, 2, 1, 0.5, 0.25, 0.125) were prepared by mixing 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution in a volume ratio of 1:1. The other three control hydrogels AHB / PC (without drug and zwitterion), AHBC / PC (with drug but without zwitterion), and AHB / PSC (with zwitterion but without drug) were prepared in the same way.

[0075] Investigation of hydrogel scavenging nitrogen free radical DPPH: First, hydrogel samples with different dry weights were immersed in 1 mL DPPH methanol-water (4 / 1, v / v) solution, incubated in the dark for 0.5 h, and then the absorbance at a wavelength of 517 nm was detected. The calculation formula for DPPH scavenging rate is as follows:

[0076]

[0077] Among them, A sample represents the absorbance of (hydrogel+DPPH), A blank represents the absorbance of the hydrogel, A control Represents the absorbance of DPPH.

[0078] Investigation of hydrogel removal of •OH: First, hydrogel samples with different dry weights were immersed in 3 mL of a mixed solution (Fenton solution) of FeSO4 (200 μM) and H2O2 (200 μM). After 5 min, 1 mL of methylene blue solution (200 μM) was added and incubated for 1 h. The absorbance at a wavelength of 664 nm was detected. The •OH removal rate was calculated as follows:

[0079]

[0080] Among them, A sample represents the absorbance of (hydrogel+Fenton+MB), A Fenton represents the absorbance of (Fenton+MB), A blank represents the absorbance of MB.

[0081] The experimental results show that ( Figure 6): AHB / PC and AHB / PSC hydrogels without chlorogenic acid have a certain DPPH scavenging ability, with a scavenging rate of about 40% at 4 mg / mL, which may be attributed to the consumption of DPPH by the phenylboronic acid structure in the gel. In contrast, the scavenging rate of DPPH by AHBC / PC and AHBC / PSC hydrogels loaded with chlorogenic acid was significantly enhanced, reaching 90% at 1 mg / mL, which may be attributed to the dual scavenging effect of chlorogenic acid and phenylboronic acid structure on DPPH. The scavenging of •OH by each group of hydrogels showed the same trend.

[0082] Example 4: Investigation of the anti-inflammatory ability of hydrogels:

[0083] RAW 264.7 cells (5 × 10 4 Cells / well) were seeded in 6-well plates. After the cells adhered to the wall, hydrogel extracts containing 6.25 μM, 12.5 μM and 25 μM chlorogenic acid were added to each well. LPS / IFN-γ was then added to make the final concentrations of LPS and IFN-γ 1 μg / mL and 40 ng / mL, respectively. After incubation for 24 h, the old culture medium was removed. RT-PCR was used to investigate the relative mRNA expression of iNOS, a marker of M1 macrophages, and Arg-1, a marker of M2 macrophages.

[0084] The experimental results show that ( Figure 7 ): Compared with M0 cells, the iNOS marker of the M1 phenotype increased significantly, and the Arg-1 marker of the M2 phenotype decreased significantly. After treatment with different concentrations of chlorogenic acid, the expression of iNOS in M1 macrophages was significantly downregulated, and the expression of Arg-1 was significantly upregulated, and it was concentration-dependent. This shows that chlorogenic acid can promote the polarization of macrophages from the pro-inflammatory M1 type to the anti-inflammatory M2 type.

[0085] Comparative Example 3: Comparison of the anti-protein adsorption ability of AHBC / PSC hydrogel and control hydrogel:

[0086] AHBC / PSC hydrogel was prepared by mixing 5 wt% AHBC precursor solution and 5 wt% PSC precursor solution in a volume ratio of 1:1. The other three control hydrogels AHB / PC (without drug and zwitterion), AHBC / PC (with drug but without zwitterion), and AHB / PSC (with zwitterion but without drug) were prepared in the same way.

[0087] The anti-protein adsorption ability of the hydrogel was quantitatively determined using a micro-BCA protein detection kit. First, 200 μL of hydrogel was spread on the bottom of a 24-well plate and PBS was added to swell until equilibrium. Then, 1 mL of 2 mg / mL bovine serum albumin (BSA) solution was added and incubated at 37°C for 2 h. Next, the hydrogel was washed three times with PBS and then immersed in a 1% sodium dodecyl sulfate solution for 2 h. Finally, the protein concentration in the sample was determined according to the instructions of the protein quantification kit, and the relative protein adsorption percentage was calculated.

[0088] The experimental results show that ( Figure 7 ): Different hydrogel groups all showed a certain ability to resist BSA protein adsorption. Compared with AHB / PC and AHBC / PC hydrogels, AHB / PS and AHBC / PSC hydrogels grafted with zwitterions showed stronger ability to resist protein adsorption.

[0089] Example 4: Investigation of drug release behavior of AHBC / PSC hydrogel in response to active oxygen in vitro:

[0090] The AHBC / PSC hydrogels were sealed in dialysis bags (MwCO 3500 Da) and immersed in 30 mL of PBS (pH 7.4) containing different concentrations of H2O2 (0, 100 μM, 300 μM, and 500 μM) and shaken at 37°C. 3 mL of release medium was drawn and 3 mL of fresh release medium was added at 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, and 120 h, respectively. The concentration of chlorogenic acid in the release medium was detected by UV-visible spectrophotometer at a wavelength of 324 nm, and its cumulative release rate was further calculated.

[0091] The experimental results show that ( Figure 8 ): In PBS solution at pH 7.4, the cumulative release rate of chlorogenic acid in the hydrogel was only 20% within 5 days. When the release medium contained 100 μM H2O2, the release rate of chlorogenic acid was significantly accelerated, and the cumulative release rate on the 5th day reached 59%, indicating that H2O2 can accelerate the breakage of phenylboronic acid. At the same time, with the increase of H2O2 concentration, the cumulative release rate was further enhanced, and when the H2O2 concentration was 500 μM, it was basically released on the 5th day. The above results show that AHBC / PSC hydrogel can respond to the ROS level at the wound site and realize the intelligent release of the drug chlorogenic acid.

[0092] Example 5: Investigation of cecal retention behavior of AHBC / PSC hydrogel in vivo

[0093] In a sterile clean bench, rats were anesthetized and depilated, and the surgical area was disinfected with ethanol. The skin and abdominal wall (about 4 cm long) were incised along the midline of the abdomen to expose the cecum. AHBC / PSC precursor solution was administered to form a hydrogel film on the surface of the cecum by in situ cross-linking, thereby covering the irregular surface of the cecum. The cecum was then carefully retracted, and the inner abdominal wall was sutured with 4-0 surgical sutures, and the outer skin was sutured with 3-0 surgical sutures. The rats were killed on the 2nd, 7th, and 14th days after surgery, and the abdominal cavity was opened to observe the residual gel on the surface of the cecum. The residual gel was carefully peeled off and weighed. Commercially available sodium hyaluronate (HA) was used as a control and the same method was used.

[0094] The experimental results show that ( Fig. 9 ): The commercially available HA hydrogel disappeared from the cecal surface on the second day, while the remaining amount of the AHBC / PSC hydrogel on the cecal surface was about 75% on the second day, and about 25% on the seventh day, and disappeared from the cecal surface on the 14th day. The above results show that compared with the commercially available HA, the AHBC / PSC hydrogel can effectively separate the damaged wound surface from the adjacent tissues during the critical period of adhesion formation (within 7 days), and disperse after the wound is completely healed on day 14, avoiding the secondary surgical removal of the barrier, reflecting good convenience.

[0095] Example 6: Investigation of cecal retention behavior of AHBC / PSC hydrogel in vivo

[0096] The construction process of the rat cecum-abdominal wall abrasion model: the rats were anesthetized and depilated, the surgical area was disinfected with ethanol, the skin and abdominal wall were incised along the midline of the abdomen (about 4 cm long), the cecum was exposed, and the cecum was rubbed back and forth with sterile medical gauze until blood spots appeared on the surface of the cecum. At the same time, a 1 cm × 2 cm injury area was cut out on the abdominal wall (including the peritoneal layer and muscle layer) on the opposite side of the cecum to form a damaged abdominal wall.

[0097] The experimental groups were as follows: ① sham group, ② model group, ③ commercial sodium hyaluronate (HA) group, ④ homemade gel AHB / PC group, ⑤ homemade gel AHB / PSC group, and ⑥ homemade gel AHBC / PSC group. The Model group did not receive any treatment and directly returned the cecum; the Sham group did not undergo abrasion, and other operations were consistent with the Model group; the HA group returned the cecum after injecting commercial sodium hyaluronate into the injury site; the homemade gel group carefully returned the cecum after the hydrogel formed a thin hydrogel in situ on the surface of the damaged cecum and abdominal wall. All groups were sutured with 4-0 thread for the inner abdominal wall and 3-0 thread for the outer skin. Finally, the surgical area was disinfected with amoxicillin solution, and the mice were returned to the cage according to the group, with free access to water and food.

[0098] On the 7th day after surgery, 6 rats were randomly selected from each group and killed after blood sampling. The abdominal cavity of the rats was immediately opened to observe the adhesion in the abdominal cavity and take photos for record. The adhesion in each group was scored according to the adhesion standard scoring method.

[0099] The experimental results show that ( Fig.10 ): No adhesion was observed in the Sham group, with a score of 0; the Model group showed large and severe adhesions between the cecum and the abdominal wall on the 7th and 14th days, with a score of approximately 4.75 points. Compared with the Model group, the score of the HA group was slightly lower, approximately 4 points. Compared with the HA group, the score of the AHB / PC gel group was approximately 2-3 points, showing a moderate anti-adhesion effect, which may be due to the good lubricity, viscoelasticity and strong tissue adhesion of the AHB / PC hydrogel, which can withstand the pressure and shear force of the abdominal cavity environment, cover the deep wound well, and play a good physical barrier effect during the critical period of PAA formation. Compared with the AHB / PC group, the score of the AHBC / PC group was further reduced to approximately 1 point, which may be due to its ability to respond to the inflammatory wound surface to release the anti-inflammatory antioxidant drug chlorogenic acid, which can remove ROS and reduce the level of inflammation. Compared with the AHBC / PC group, the anti-adhesion effect of the AHBC / PSC group was further enhanced, with a score of approximately 0.125 points, which may be attributed to its following three effects: ① good mechanical properties, ② responsive chlorogenic acid to remove ROS and reduce inflammation levels, and ③ zwitterions to reduce fibrin adsorption and fibroblast adhesion, ultimately showing the most significant anti-adhesion effect.

Claims

1. An anti-inflammatory, anti-oxidative and anti-protein adsorption double cross-linked hydrogel, characterized in that: The invention is composed of two gel precursor materials, a polyvinyl alcohol derivative PSC and a hyaluronic acid derivative AHBC. The structural feature of the PSC is that p-hydroxybenzaldehyde and sulfated betaine are covalently modified on some hydroxyl groups of the polyvinyl alcohol. The structural feature of the AHBC is that hyaluronic acid is co-modified with 3-fluorophenylboronic acid and adipic acid hydrazide groups, and anti-inflammatory and antioxidant drugs containing polyphenol groups are further grafted on the phenylboronic acid through active oxygen responsive borate bonds. After the AHBC solution is mixed with the PSC solution, the hydrazide group and the boric acid group in the AHBC react with the aldehyde group and the 1,3-diol group on the PSC respectively to generate dynamic covalent acylhydrazone bonds and borate bonds, thereby obtaining a double-crosslinked active oxygen responsive anti-inflammatory and antioxidant hydrogel. In the PSC structure, n is a natural number between 250 and 2000; In the AHBC structure, n is a natural number ranging from 25 to 1000, and A4 is an anti-inflammatory and antioxidant drug containing a polyphenol group.

2. The anti-inflammatory, antioxidant and anti-protein adsorption double cross-linked hydrogel according to claim 1, characterized in that: The anti-inflammatory and antioxidant drug containing polyphenol groups is one of chlorogenic acid, epigallocatechin gallate, and tannic acid; the degree of substitution of the B1 group in the PSC structure is 0.1%-0.5%, and the degree of substitution of the B2 group is 1%-5%; the degree of substitution of the A1 group in the AHBC structure is 30%-40%, and the degree of substitution of the A2 group is 30%-40%.

3. The method for preparing an anti-inflammatory, anti-oxidative and anti-protein adsorption double cross-linked hydrogel according to claim 1, characterized in that: The following steps are involved: Step 1, synthesizing the gel precursor material AHBC; Step 2, synthesizing the gel precursor material PSC; Step 3, dissolving AHBC and PSC in an aqueous medium to prepare a solution, and then mixing the AHBC solution and the PSC solution to prepare an anti-inflammatory, antioxidant and anti-protein adsorption double cross-linked hydrogel.

4. The method for preparing an anti-inflammatory, anti-oxidative and anti-protein adsorption double cross-linked hydrogel according to claim 3, characterized in that: The synthesis of AHBC comprises the following steps: first, PBA is used as a raw material to synthesize PBA-NH2, then PBA-NH2 and hyaluronic acid HA are used as raw materials to synthesize HA-PBA through an amide condensation reaction, then HA-PBA and ADH are used as raw materials to synthesize ADH-HA-PBA through an amide condensation reaction, and finally, ADH-HA-PBA is reacted with an anti-inflammatory and antioxidant drug C containing a polyphenol group to synthesize a precursor material AHBC; The synthesis of the PSC comprises the following steps: firstly, DPE is used as a synthetic raw material to synthesize DPE-SB, then PVA is reacted with succinic anhydride to synthesize PVA-COOH, then PVA-COOH is reacted with DPE-SB to synthesize PVA(SB), and finally PVA(SB) is reacted with p-hydroxybenzaldehyde to synthesize PSC. .

5. The method for preparing the anti-inflammatory, antioxidant and anti-protein adsorption double cross-linked hydrogel according to claim 3, characterized in that The concentration of the AHBC is 2.5wt%~7.5wt%; the concentration of the PSC is 2.5wt%~7.5wt%; the mixing method of the AHBC solution and the PSC solution is in-situ mixing of the application part; the mixing method is injection or spray mixing.

6. Use of the anti-inflammatory, antioxidant and anti-protein adsorption double cross-linked hydrogel according to claims 1-5 in the preparation of a biological barrier against postoperative tissue adhesion.

7. The use according to claim 6, characterized in that: The postoperative tissue adhesion includes any one or more of abdominal adhesion, uterine adhesion, and pericardial adhesion.

Citation Information

Cited By

  • Hydrogel adhesive for repairing acute and chronic infected wounds and inhibiting scars as well as preparation method and application of hydrogel adhesive

    CN121243449A

  • Hydrogel composition and manufacturing method thereof

    TWI919933B